Literature DB >> 23325678

Circulating antibodies and macrophages as modulators of adenovirus pharmacology.

Reeti Khare1, Matthew L Hillestad, Zhili Xu, Andrew P Byrnes, Michael A Barry.   

Abstract

Adenovirus serotype 5 (Ad5) naturally infects the liver after intravenous injection, making it a candidate for hepatocyte-directed gene transfer. While Ad5 can be efficient, most of the dose is destroyed by liver Kupffer cells before it can reach hepatocytes. In contrast, Ad5 bearing the hexon from Ad6 (Ad5/6) evades Kupffer cells. While Ad5/6 dramatically increases hepatocyte transduction in BALB/c mice, it has surprisingly little effect on C57BL/6 mice. To determine the source of this strain-specific difference, the roles of Kupffer cells, liver sinusoidal endothelial cells (LSECs), hepatocytes, scavenger receptors, clotting factors, and immunoglobulins were analyzed. The numbers of Kupffer cells and LSECs, the level of clotting factor X, and hepatocyte infectibility did not differ between different strains of mice. In contrast, high levels of immunoglobulins correlated negatively with Ad5 liver transduction in different mouse strains. Removal of immunoglobulins by use of Rag-deficient mice restored Ad5 transduction to maximal levels. Removal of Kupffer cells by predosing or by testing in colony-stimulating factor knockout mice restored Ad5 transduction in the presence of immunoglobulins. Partial reconstitution of IgM in Rag mice resulted in significant reductions in liver transduction by Ad5 but not by Ad5/6. These data suggest a role for IgM-mediated clearance of Ad5 via Kupffer cells and may explain the mechanism by which Ad5/6 evades these cells. These mechanisms may play a vital role in Ad pharmacology in animals and in humans.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23325678      PMCID: PMC3624219          DOI: 10.1128/JVI.01392-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

Review 1.  The importance of natural IgM: scavenger, protector and regulator.

Authors:  Michael R Ehrenstein; Clare A Notley
Journal:  Nat Rev Immunol       Date:  2010-10-15       Impact factor: 53.106

2.  Adenovirus activates complement by distinctly different mechanisms in vitro and in vivo: indirect complement activation by virions in vivo.

Authors:  Jie Tian; Zhili Xu; Jeffrey S Smith; Sean E Hofherr; Michael A Barry; Andrew P Byrnes
Journal:  J Virol       Date:  2009-03-25       Impact factor: 5.103

3.  Analyzing antibody-Fc-receptor interactions.

Authors:  Falk Nimmerjahn; Jeffrey V Ravetch
Journal:  Methods Mol Biol       Date:  2008

4.  Generation of a Kupffer cell-evading adenovirus for systemic and liver-directed gene transfer.

Authors:  Reeti Khare; Shannon M May; Francesco Vetrini; Eric A Weaver; Donna Palmer; Amanda Rosewell; Nathan Grove; Philip Ng; Michael A Barry
Journal:  Mol Ther       Date:  2011-04-19       Impact factor: 11.454

5.  Characterization of species C human adenovirus serotype 6 (Ad6).

Authors:  Eric A Weaver; Mathew L Hillestad; Reeti Khare; Donna Palmer; Philip Ng; Michael A Barry
Journal:  Virology       Date:  2011-01-20       Impact factor: 3.616

6.  Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agents.

Authors:  Elena V Shashkova; Shannon M May; Michael A Barry
Journal:  Virology       Date:  2009-09-18       Impact factor: 3.616

7.  Scavenger receptor A: a new route for adenovirus 5.

Authors:  Hidde J Haisma; Marije Boesjes; Antoine M Beerens; Barry W A van der Strate; David T Curiel; Annette Plüddemann; Siamon Gordon; Anna Rita Bellu
Journal:  Mol Pharm       Date:  2009 Mar-Apr       Impact factor: 4.939

8.  Redundant and synergistic mechanisms control the sequestration of blood-born adenovirus in the liver.

Authors:  Nelson C Di Paolo; Nico van Rooijen; Dmitry M Shayakhmetov
Journal:  Mol Ther       Date:  2009-02-17       Impact factor: 11.454

9.  Macrophage depletion combined with anticoagulant therapy increases therapeutic window of systemic treatment with oncolytic adenovirus.

Authors:  Elena V Shashkova; Konstantin Doronin; Julien S Senac; Michael A Barry
Journal:  Cancer Res       Date:  2008-07-15       Impact factor: 12.701

Review 10.  Advances and future challenges in adenoviral vector pharmacology and targeting.

Authors:  Reeti Khare; Christopher Y Chen; Eric A Weaver; Michael A Barry
Journal:  Curr Gene Ther       Date:  2011-08       Impact factor: 4.391

View more
  26 in total

Review 1.  Innate immunity to adenovirus: lessons from mice.

Authors:  Svetlana Atasheva; Jia Yao; Dmitry M Shayakhmetov
Journal:  FEBS Lett       Date:  2019-12-08       Impact factor: 4.124

Review 2.  Adenovirus sensing by the immune system.

Authors:  Svetlana Atasheva; Dmitry M Shayakhmetov
Journal:  Curr Opin Virol       Date:  2016-09-14       Impact factor: 7.090

3.  Helper-dependent adenovirus achieve more efficient and persistent liver transgene expression in non-human primates under immunosuppression.

Authors:  C Unzu; I Melero; S Hervás-Stubbs; A Sampedro; U Mancheño; A Morales-Kastresana; I Serrano-Mendioroz; R E de Salamanca; A Benito; A Fontanellas
Journal:  Gene Ther       Date:  2015-07-23       Impact factor: 5.250

4.  Impact of natural IgM concentration on gene therapy with adenovirus type 5 vectors.

Authors:  Qi Qiu; Zhili Xu; Jie Tian; Rituparna Moitra; Sreenivasulu Gunti; Abner L Notkins; Andrew P Byrnes
Journal:  J Virol       Date:  2014-12-31       Impact factor: 5.103

5.  Pathology in Permissive Syrian Hamsters after Infection with Species C Human Adenovirus (HAdV-C) Is the Result of Virus Replication: HAdV-C6 Replicates More and Causes More Pathology than HAdV-C5.

Authors:  Ann E Tollefson; Baoling Ying; Jacqueline F Spencer; John E Sagartz; William S M Wold; Karoly Toth
Journal:  J Virol       Date:  2017-04-28       Impact factor: 5.103

Review 6.  Innate immunity to adenovirus.

Authors:  Rodinde Hendrickx; Nicole Stichling; Jorien Koelen; Lukasz Kuryk; Agnieszka Lipiec; Urs F Greber
Journal:  Hum Gene Ther       Date:  2014-04-08       Impact factor: 5.695

Review 7.  Retargeting adenoviruses for therapeutic applications and vaccines.

Authors:  Michael A Barry; Jeffrey D Rubin; Shao-Chia Lu
Journal:  FEBS Lett       Date:  2020-02-03       Impact factor: 4.124

8.  Diminished Innate Antiviral Response to Adenovirus Vectors in cGAS/STING-Deficient Mice Minimally Impacts Adaptive Immunity.

Authors:  Daniela Anghelina; Eric Lam; Erik Falck-Pedersen
Journal:  J Virol       Date:  2016-06-10       Impact factor: 5.103

9.  Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers.

Authors:  Joao Santos; Camilla Heiniö; Dafne Quixabeira; Sadia Zafar; James Clubb; Santeri Pakola; Victor Cervera-Carrascon; Riikka Havunen; Anna Kanerva; Akseli Hemminki
Journal:  Cells       Date:  2021-04-22       Impact factor: 6.600

Review 10.  Innate immune surveillance of the circulation: A review on the removal of circulating virions from the bloodstream.

Authors:  Stephanie E Ander; Frances S Li; Kathryn S Carpentier; Thomas E Morrison
Journal:  PLoS Pathog       Date:  2022-05-05       Impact factor: 7.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.